Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Can Iclusig Return To Market? Ariad Sees Path Through Restricted Distribution REMS

04 Nov 2013

• By Sue Sutter

Related Content

AstraZeneca VP Detlev Biniszkiewicz On Building An Oncology Strategy In China And Asia

31 Jan 2012

Ariad’s Leukemia Drug <em>Iclusig</em> Sails Through FDA In Less Than 3 Months

17 Dec 2012

FDA Re-Approves Tysabri, Recommends Second-Line Use

05 Jun 2006

Tysabri Could Return In Fall; Marketing Suspended By Biogen Idec And Elan

28 Feb 2005

Related Companies

ARIAD Pharmaceuticals, Inc.

Bristol Myers Squibb Company

Novartis AG

Biogen, Inc.

AstraZeneca PLC

Additional Topics

United States Safety BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.